Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke

Annals of Neurology

Volumn 71, Issue 5, 2012, Pages 624-633

  Pfeilschifter, Waltraud ^a   Bohmann, Ferdinand ^a   Baumgarten, Peter ^a   Mittelbronn, Michel ^a   Pfeilschifter, Josef ^a   Lindhoff Last, Edelgard ^a   Steinmetz, Helmuth ^a   Foerch, Christian ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; DABIGATRAN ETEXILATE; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; BLOOD VOLUME; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; STROKE;

ANIMALS; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; CEREBRAL HEMORRHAGE; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; FIBRINOLYTIC AGENTS; MICE; MICE, INBRED C57BL; STROKE; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

EID: 84860222458     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23558     Document Type: Article

References (36)

1. Stangier J, Clemens A,. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009; 15: 9S-16S.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
3. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38: 1655-1711.
4. Matute AC, Guillán M, Garcia-Caldentey J, et al. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost 2011; 106: 178-179.
5. De Smedt A, De Raedt S, Nieboer K, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis 2010; 30: 533-534.
6. Naranjo IC, Portilla-Cuenca JC, Jiménez Caballero PE, et al. Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran. Cerebrovasc Dis 2011; 32: 614-615.
7. Dempfle CE, Hennerici MG,. Dabigatran and stroke thrombolysis. Cerebrovasc Dis 2010; 30: 203-205.
8. Wienen W, Stassen JM, Priepke H, et al. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost 2007; 98: 333-338.
9. Lauer A, Cianchetti FA, Van Cott E, et al. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Circulation 2011; 124: 1654-1662.
10. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
11. Foerch C, Arai K, Jin G, et al. Experimental model of warfarin-associated intracerebral hemorrhage. Stroke 2008; 39: 3397-3404.
12. Foerch C, Arai K, Van Cott EM, et al. Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin associated intracerebral hemorrhage. J Cereb Blood Flow Metab 2009; 29: 1015-1021.
13. Pfeilschifter W, Spitzer D, Czech-Zechmeister B, et al. Increased risk of hemorrhagic transformation in ischemic stroke occurring during warfarin anticoagulation-an experimental study in mice. Stroke 2011; 42: 1116-1121.
14. A-priori sample size calculation. http://www.danielsoper.com/ statcalc/calc47.aspx. Accessed 26.02.2011.
15. Seifert J, Britz P,. Rqube. Version 1.00.8.100. Trier, Germany: University of Trier, 2007. Available at: Accessed February 3, 2011.
16. Chen J, Sanberg PR, Li Y, et al. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke 2001; 32: 2682-2688.
17. Härtter S, Yamamura N, Stangier J, et al. Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate. Thromb Haemost 2012; 107: 260-269.
18. Sun L, Zhou W, Ploen R, et al. Rapid reversal of anticoagulation prevents excessive secondary hemorrhage after thrombolysis in a thromboembolic model in rats. Stroke 2011; 42: 3524-3529.
19. Pfeilschifter W, Spitzer D, Pfeilschifter J, et al. Warfarin anticoagulation exacerbates the risk of hemorrhagic transformation after rt-PA treatment in experimental stroke: therapeutic potential of PCC. PLoS One 2011; 6: e26087.
20. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am J Cardiol 2007; 100: 1419-1426.
21. European Medical Agencies. Available at: Accessed January 16, 2012.
22. Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011; 9: 2168-2175.
23. Wang X, Tsuji K, Lee S, et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004; 35: 2726-2730.
24. Warach S, Latour LL,. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke 2004; 35: 2659-2661.
25. Nielsen VG, Cohen BM, Cohen E,. Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography: critical roles of fibrinogen and factors II, VII, X and XII. Acta Anaesthesiol Scand 2005; 49: 222-231.
26. Di Nisio M, Middeldorp S, Buller HR,. Direct thrombin inhibitors. N Engl J Med 2005; 353: 1028-1040.
27. Xiao Z, Theroux P,. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 251-256.
28. Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599.
29. Eickelboom JW, Wallentin J, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2001; 123: 2363-2372.
30. Chong CA, Chiu L,. Dabigatran and acute stroke thrombolysis. Cerebrovasc Dis 2010; 20: 202.
31. Stangier J, Stahle H, Rathgen K, Fuhr R,. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 47-59.
32. Stangier J, Clemens A,. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009; 15 (suppl 1): 9S-16S.
33. Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004; 2: 1573-1580.
34. Legrand M, Mateo J, Aribaud A,. The use of dabigatran in elderly patients. Arch Intern Med 2011; 171: 1285-1288.
35. Tsang VC, Wyatt CR, Damian RT,. Comparative thermometric coagulation studies of plasmas from normal outbred Swiss Webster mice and persons. Am J Vet Res 1979; 40: 857-862.
36. Tsakiris DA, Scudder L, Hodivala-Dilke K, Hynes RO, Coller BS,. Hemostasis in the mouse (Mus musculus): a review. Thromb Haemost 1999; 81: 177-188.